Rationale for IL-37 as a novel therapeutic agent in inflammation

Claudia A Nold-Petry; Marcel F Nold

doi:10.1080/1744666X.2022.2108792

Rationale for IL-37 as a novel therapeutic agent in inflammation

Expert Rev Clin Immunol. 2022 Dec;18(12):1203-1206. doi: 10.1080/1744666X.2022.2108792. Epub 2022 Aug 16.

Authors

Claudia A Nold-Petry^{1

2}, Marcel F Nold^{1

2

3}

Affiliations

¹ Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia.
² Department of Paediatrics, School of Clinical Sciences, Monash University, Melbourne, Australia.
³ Monash Newborn, Monash Children's Hospital, Melbourne, Australia.

PMID: 35916240
DOI: 10.1080/1744666X.2022.2108792

No abstract available

Keywords: Acute inflammation; anti-inflammatory treatment; chronic inflammation; cytokine; disease mechanisms; immunology; interleukin 37; novel therapeutic; translational research.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Inflammation* / drug therapy
Interleukin-1* / therapeutic use

Substances

Interleukin-1